Status:
RECRUITING
Role of Adiposomes in Endothelial Dysfunction
Lead Sponsor:
University of Illinois at Chicago
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Obesity
Diabetes
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
The development of type II diabetes (T2D) is strongly associated with obesity and both are well-established risk factors for cardiovascular disease. Knowing that vascular dysfunction is an early event...
Eligibility Criteria
Inclusion
- BMI ≥ 35 kg/m2
- Between ages 18-50 years
- Not pregnant
- Diabetic (Current use of diabetes medication or fasting glucose ≥126 mg/dL)
- Medical clearance to participate in a moderate-intensity exercise program
Exclusion
- Pregnant women
- Current smokers
- Currently abusing alcohol or drugs
- Chronic heart, liver, or kidney diseases, autoimmune diseases, or cancer
- Non-English speakers
- History of allergic reactions to lidocaine
Key Trial Info
Start Date :
May 16 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05199454
Start Date
May 16 2022
End Date
December 31 2026
Last Update
January 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Illinois at Chicago
Chicago, Illinois, United States, 60612